Aethlon Medical's Presentation on Evolving Long COVID Research
Exploring the Hemopurifier® Affinity Resin's Effectiveness in Long COVID Cases
Aethlon Medical, Inc. (Nasdaq: AEMD), a company dedicated to creating innovative therapeutic solutions, has announced promising developments ahead of its upcoming poster presentation at an important symposium focused on Long COVID and related syndromes. At this event, vital research regarding Aethlon's Hemopurifier® will be shared, delving into its potential in binding to extracellular vesicles (EVs) present in Long COVID patients.
Long COVID continues to present a myriad of symptoms for countless individuals post their SARS-CoV-2 infection, often leading to prolonged challenges such as extreme fatigue, shortness of breath, and cognitive impairments. Current estimates reveal that this condition impacts millions of people, highlighting a growing public health concern that necessitates effective treatment options.
With rising attention and significant investment in research surpassing $1 billion, the quest for a successful treatment remains unfulfilled as traditional approaches have yet to yield results. The Hemopurifier® emerges as an exciting investigational device designed to cleanse the blood by eliminating detrimental EVs, which have been linked to the manifestation of Long COVID.
These extracellular vesicles are essential elements in cell communication, with their size ranging between 50 to 500 nm, and they play a role in various physiological processes. Research suggests that EVs could contain viral components and molecules contributing to inflammation and abnormal clotting, which are of particular concern in Long COVID cases.
Aethlon's Hemopurifier® employs a proprietary approach using a special affinity resin that binds to specific targets on EVs to remove them efficiently from circulation. This device has previously shown success in other severe viral infections, raising hope for its application in treating the aftermath of COVID-19.
Collaborative studies conducted with esteemed institutions, such as the University of California San Francisco Medical Center, have been pivotal in assessing the presence of mannosylated EVs in individuals suffering from Long COVID. This information will form a substantial part of the poster presentation, outlining findings on the binding capabilities of various sized EVs to the innovative affinity resin developed by Aethlon.
The scheduled details for the presentation are as follows:
Title: Extracellular Vesicles from Participants with Long COVID are Mannosylated and Bind to the Galanthus Nivalis Agglutinin Resin in the Aethlon Hemopurifier®
Authors: Miguel Pesqueira, Rosalia de Necochea Campion, Thomas Dalhuisen, Emily A. Fehrman, Jeffrey N. Martin, Timothy J. Henrich, Steven G. Deeks, Michael J. Peluso, and Steven P. LaRosa
Presenter: Steven P. LaRosa, M.D., Chief Medical Officer, Aethlon Medical, Inc.
Poster Number: 2001
Date and Time: August 12, 2025, at 7:30 PM MDT.
The insights from this presentation will be made publicly available on Aethlon Medical's corporate website after the event, furthering the dialogue on effective treatments for Long COVID.
Understanding Aethlon and the Hemopurifier®
Aethlon Medical is at the forefront of medical innovation, focusing its efforts on developing the Hemopurifier, which is aimed at addressing significant health challenges, from cancers to life-threatening infections. This advanced immune system support device has shown promise in binding and removing harmful pathogens, making it a key player in oncological and infectious disease therapies. The Hemopurifier is recognized by the FDA as a Breakthrough Device for its noteworthy applications, particularly concerning patients unresponsive to standard care.
The breakthroughs achieved in pre-clinical studies underscore the Hemopurifier's potential to transform treatment protocols in both cancer and virus-related health crises, particularly in cases where conventional therapies have failed.
For more details about Aethlon Medical and their pioneering work, interested parties may visit their official website.
Company Contact:
Jim Frakes
Chief Executive Officer and Chief Financial Officer
Aethlon Medical, Inc.
Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
Frequently Asked Questions
What is Aethlon Medical known for?
Aethlon Medical focuses on developing therapeutic products for cancer and life-threatening infectious diseases, including the Hemopurifier.
What is the goal of the Hemopurifier?
The Hemopurifier aims to remove harmful extracellular vesicles from the blood to mitigate associated health risks.
When will the poster presentation take place?
The poster presentation is scheduled for August 12, 2025, at 7:30 PM MDT.
Where can I find more information about Aethlon Medical's research?
Additional information will be available on Aethlon Medical's official website following the presentation.
Why is research on Long COVID important?
Research on Long COVID is crucial as it affects millions and understanding treatments could greatly improve patients' quality of life.
